Trial Profile

A Phase 2 (POC) investigator-sponsored study of anti-S. aureus phages therapy in in diabetic foot ulcers

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 27 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PP 1493 (Primary) ; PP 1815 (Primary)
Indications Diabetic foot ulcer
Focus Adverse reactions; Proof of concept; Therapeutic Use
Acronyms PhagoPied

Most Recent Events

25 Sep 2024 According to a PHAXIAM Therapeutics media release, this study is ready for First-Patient-In, expected before the end of this year.
15 May 2024 According to a PHAXIAM Therapeutics media release, this clinical study is targeting DFU infections due to mono-bacterial aureus infection in 60 diabetic patients to be enrolled across 10 French hospitals.
01 Jul 2022 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com